the broad spectrum of EGCG to
other diseases and variable target enzymes offers some limitations. In view of this, 32 EGCG analogues
were screened at S-Adnosyl-L-homocysteine (SAH) binding pocket of DNMTs and procyanidin B2–3,
30-di-O-gallate (procyanidin B2) was obtained as potent inhibitor having medicinally relevant chemical
space. Further, in vitro analysis demonstrates the efficiency of procyanidin B2 in attenuating DNMT
activity at IC50 of 6.88 ± 0.647 lM and subsequently enhancing the expression of DNMT target genes,
E-cadherin, Maspin and BRCA1.